|
rs113488022
|
|
|
0.900 |
GeneticVariation |
BEFREE |
Current clinical guidelines recommend mutation analysis for select codons in KRAS and NRAS exons 2, 3, and 4 and BRAF V600E to guide therapy selection and prognostic stratification in advanced colorectal cancer.
|
31589789 |
2020 |
|
rs10795668
|
|
G |
0.900 |
GeneticVariation |
GWASCAT |
Large-Scale Genome-Wide Association Study of East Asians Identifies Loci Associated With Risk for Colorectal Cancer.
|
30529582 |
2019 |
|
rs113488022
|
|
|
0.900 |
GeneticVariation |
BEFREE |
Moreover, this method was proven to distinguish the BRAF V600E mutant from the wild type based on intrinsic differences by using a total of 312 CRC tissue samples paraffin-embedded, deparaffinized, and stained.
|
31208050 |
2019 |
|
rs113488022
|
|
|
0.900 |
GeneticVariation |
BEFREE |
BRAF V600E and SRC mutations are important molecular markers which can predict prognosis and conversion surgery in Stage IV CRC.
|
30792536 |
2019 |
|
rs113488022
|
|
|
0.900 |
GeneticVariation |
BEFREE |
<i>BRAF</i> (v-raf murine sarcoma viral oncogene homolog B1) V600E mutant colorectal cancer is associated with short survival.
|
30719102 |
2019 |
|
rs113488022
|
|
|
0.900 |
GeneticVariation |
BEFREE |
These tumors are less likely to have microsatellite instability than CRC with a V600E BRAF mutation and often harbor a KRAS or NRAS mutation.
|
31185985 |
2019 |
|
rs113488022
|
|
|
0.900 |
GeneticVariation |
BEFREE |
MLH1 promoter methylation and V600E BRAF mutation analysis were investigated on 61 CRCs.
|
31609810 |
2019 |
|
rs113488022
|
|
|
0.900 |
GeneticVariation |
BEFREE |
The absence of BRAF V600E mutation separates LLS colorectal carcinomas from MLH1-methylated colorectal carcinomas with CIMP-positive phenotype.
|
30575961 |
2019 |
|
rs113488022
|
|
|
0.900 |
GeneticVariation |
BEFREE |
Overall, IHC with anti-BRAF V600E (VE1) antibody using recommended protocol with OptiView detection is optimal for detection of BRAF V600E mutation in CRC.
|
29127628 |
2019 |
|
rs113488022
|
|
|
0.900 |
GeneticVariation |
BEFREE |
The FDA-approved anti-helminthic drug rafoxanide was recently reported to antagonize the oncogenic function of the BRAF V600E mutant protein, commonly found in CRCs, as well as to inhibit the proliferation of skin cancer cells.
|
31351087 |
2019 |
|
rs113488022
|
|
|
0.900 |
GeneticVariation |
BEFREE |
Colorectal cancer (CRC) with the V600E mutation of B-Raf proto-oncogene serine/threonine kinase (BRAF<sup>V600E</sup>) mutation is insensitive to chemotherapy and is indicative of a poor patient prognosis.
|
30854056 |
2019 |
|
rs113488022
|
|
|
0.900 |
GeneticVariation |
BEFREE |
Circulating 25(OH)D was also inversely associated with <i>BRAF</i> V600E-positive colorectal cancer (per 25 nmol/L increment: HR, 0.71; 95% CI, 0.50-1.01).
|
30842127 |
2019 |
|
rs113488022
|
|
|
0.900 |
GeneticVariation |
BEFREE |
Previous studies have reported that rafoxanide, as an inhibitor of BRAF V600E mutant protein, inhibits the growth of colorectal cancer, multiple myeloma, and skin cancer.
|
31678170 |
2019 |
|
rs113488022
|
|
|
0.900 |
GeneticVariation |
BEFREE |
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E-Mutated Colorectal Cancer.
|
31566309 |
2019 |
|
rs113488022
|
|
|
0.900 |
GeneticVariation |
BEFREE |
Non-V600E BRAF mutations and EGFR signaling pathway in colorectal cancer.
|
30963570 |
2019 |
|
rs113488022
|
|
|
0.900 |
GeneticVariation |
BEFREE |
The US Food and Drug Administration approved a liquid biopsy test for EGFR-activating mutations in patients with non-small-cell lung cancer as a companion diagnostic for therapy selection. ctDNA also allows for the identification of mutations selected by treatment such as EGFR T790M in non-small-cell lung cancer. ctDNA can also detect mutations such as KRAS G12V in colorectal cancer and BRAF V600E/V600K in melanoma.
|
30883505 |
2019 |
|
rs16892766
|
|
C |
0.900 |
GeneticVariation |
GWASCAT |
Association analyses identify 31 new risk loci for colorectal cancer susceptibility.
|
31089142 |
2019 |
|
rs16892766
|
|
C |
0.900 |
GeneticVariation |
GWASCAT |
Novel Common Genetic Susceptibility Loci for Colorectal Cancer.
|
29917119 |
2019 |
|
rs16892766
|
|
C |
0.900 |
GeneticVariation |
GWASCAT |
Discovery of common and rare genetic risk variants for colorectal cancer.
|
30510241 |
2019 |
|
rs3802842
|
|
C |
0.900 |
GeneticVariation |
GWASCAT |
Novel Common Genetic Susceptibility Loci for Colorectal Cancer.
|
29917119 |
2019 |
|
rs3802842
|
|
C |
0.900 |
GeneticVariation |
GWASCAT |
Large-Scale Genome-Wide Association Study of East Asians Identifies Loci Associated With Risk for Colorectal Cancer.
|
30529582 |
2019 |
|
rs4444235
|
|
C |
0.900 |
GeneticVariation |
GWASCAT |
Novel Common Genetic Susceptibility Loci for Colorectal Cancer.
|
29917119 |
2019 |
|
rs4444235
|
|
|
0.900 |
GeneticVariation |
BEFREE |
The SNP rs4444235 at 14q22.2 interacted with regular exercise in colorectal cancer (p<sub>case-only</sub> = 2.4 × 10<sup>- 3</sup>, p<sub>case-control</sub> = 1.5 × 10<sup>- 3</sup>).
|
31849324 |
2019 |
|
rs4939827
|
|
T |
0.900 |
GeneticVariation |
GWASCAT |
Large-Scale Genome-Wide Association Study of East Asians Identifies Loci Associated With Risk for Colorectal Cancer.
|
30529582 |
2019 |
|
rs4939827
|
|
T |
0.900 |
GeneticVariation |
GWASCAT |
Novel Common Genetic Susceptibility Loci for Colorectal Cancer.
|
29917119 |
2019 |